CO2022017618A2 - Antagonistas del receptor de adenosina a2a - Google Patents
Antagonistas del receptor de adenosina a2aInfo
- Publication number
- CO2022017618A2 CO2022017618A2 CONC2022/0017618A CO2022017618A CO2022017618A2 CO 2022017618 A2 CO2022017618 A2 CO 2022017618A2 CO 2022017618 A CO2022017618 A CO 2022017618A CO 2022017618 A2 CO2022017618 A2 CO 2022017618A2
- Authority
- CO
- Colombia
- Prior art keywords
- receptor antagonists
- adenosine receptor
- compounds
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006823.5A GB202006823D0 (en) | 2020-05-07 | 2020-05-07 | Antagonist compounds |
| GBGB2019922.0A GB202019922D0 (en) | 2020-12-16 | 2020-12-16 | Antagonist compounds |
| PCT/GB2021/051106 WO2021224636A1 (en) | 2020-05-07 | 2021-05-06 | Antagonists of the adenosine a2a receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022017618A2 true CO2022017618A2 (es) | 2023-02-16 |
Family
ID=75977772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0017618A CO2022017618A2 (es) | 2020-05-07 | 2022-12-06 | Antagonistas del receptor de adenosina a2a |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12617796B2 (enExample) |
| EP (1) | EP4146654A1 (enExample) |
| JP (2) | JP7724239B2 (enExample) |
| KR (1) | KR20230035236A (enExample) |
| CN (2) | CN115996929B (enExample) |
| AU (1) | AU2021266433A1 (enExample) |
| BR (1) | BR112022022437A2 (enExample) |
| CA (1) | CA3181354A1 (enExample) |
| CL (1) | CL2022003055A1 (enExample) |
| CO (1) | CO2022017618A2 (enExample) |
| EC (1) | ECSP22091613A (enExample) |
| GB (1) | GB2609879B (enExample) |
| IL (2) | IL297963A (enExample) |
| MX (1) | MX2022013946A (enExample) |
| PE (1) | PE20230769A1 (enExample) |
| PH (1) | PH12022552987A1 (enExample) |
| WO (1) | WO2021224636A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023114157A2 (en) * | 2021-12-17 | 2023-06-22 | Merck Sharp & Dohme Llc | Pyrazolopyrimidine derivatives and methods of use thereof for the treatment of herpesviruses |
| CN116283994B (zh) * | 2021-12-20 | 2025-01-07 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的杂环化合物 |
| EP4467545A4 (en) * | 2022-01-18 | 2026-01-21 | Jiangsu Yayo Biotechnology Co Ltd | NEW TYPE OF COMPOUND PYRAZOLOPYRIMIDINE AND ASSOCIATED COMPOSITION, PREPARATION PROCESS AND USE |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| WO2025054448A1 (en) * | 2023-09-08 | 2025-03-13 | Satellos Bioscience Inc. | Ap2 associated kinase 1 inhibitors and uses thereof |
| TW202535406A (zh) | 2023-10-30 | 2025-09-16 | 美商壯生和壯生企業創新公司 | 用於治療肺癌之a2a受體拮抗劑 |
| WO2025123253A1 (en) | 2023-12-13 | 2025-06-19 | Johnson & Johnson Enterprise Innovation Inc. | Pharmaceutical compositions of an a2a receptor antagonist |
| WO2025123251A1 (en) | 2023-12-13 | 2025-06-19 | Johnson & Johnson Enterprise Innovation Inc. | Crystalline forms of a2a receptor antagonist, preparation methods, and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025202955A1 (en) | 2024-03-28 | 2025-10-02 | Pi Industries Ltd. | Fused bicyclic compounds and their use as pest control agents |
| CN120093763A (zh) * | 2025-03-25 | 2025-06-06 | 上海天龙生物科技有限公司 | 治疗前列腺疾病和腺体类散结节的药物组合物及其应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3910907A (en) | 1973-07-09 | 1975-10-07 | Icn Pharmaceuticals | Pyrazolo(1,5-a)-1,3,5-triazines |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| ATE257703T1 (de) | 1997-10-27 | 2004-01-15 | Takeda Chemical Industries Ltd | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes |
| AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6605623B1 (en) | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6525069B1 (en) | 1998-12-18 | 2003-02-25 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2347909A1 (en) | 1998-12-18 | 2000-06-22 | Joseph B. Santella, Iii | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| ATE302005T1 (de) | 1998-12-18 | 2005-09-15 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| EP1156807A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| AU2057200A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
| WO2001010865A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | p38MAP KINASE INHIBITORS |
| EP1268474A2 (en) | 2000-03-30 | 2003-01-02 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
| WO2001098270A2 (en) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1363881A2 (en) | 2000-06-21 | 2003-11-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| EP1364949A4 (en) | 2001-02-02 | 2005-11-23 | Takeda Pharmaceutical | JNK INHIBITOR |
| ATE404568T1 (de) | 2001-03-14 | 2008-08-15 | Gruenenthal Gmbh | Substituierte thiazolopyrimidine als analgetika |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| KR20030083016A (ko) | 2001-03-28 | 2003-10-23 | 브리스톨-마이어스스퀴브컴파니 | 신규 타이로신 카이나제 억제제 |
| EP1402900A1 (en) | 2001-06-11 | 2004-03-31 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
| EP1441732A2 (en) | 2001-11-08 | 2004-08-04 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivative and pharmaceutical use thereof |
| KR20040097375A (ko) * | 2002-04-23 | 2004-11-17 | 시오노기 앤드 컴파니, 리미티드 | 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제 |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| JP4638355B2 (ja) | 2003-12-26 | 2011-02-23 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| PL380764A1 (pl) | 2003-12-31 | 2007-03-19 | Schering-Plough Ltd. | Kontrolowanie pasożytów u zwierząt za pomocą stosowania imidazo [1,2-b] pirydazynowych pochodnych |
| GB0401336D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2006070943A1 (ja) | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| JP2008542323A (ja) * | 2005-06-01 | 2008-11-27 | ユセベ ファルマ ソシエテ アノニム | ２−オキソ−１−ピロリジン誘導体、その製造方法及びその使用 |
| BRPI0812504B8 (pt) * | 2007-06-21 | 2021-05-25 | Cara Therapeutics Inc | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero |
| WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| EP2103614A1 (en) | 2008-03-18 | 2009-09-23 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2402344A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| EP2402343A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole-fused bicyclic compounds |
| EP2402345A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| EP2402337A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
| TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 |
| WO2012100342A1 (en) * | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| UA114490C2 (uk) | 2011-10-06 | 2017-06-26 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mі)динілпіразоли як фунгіциди |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| CN104418821A (zh) | 2013-08-22 | 2015-03-18 | 四川大学华西医院 | 2,4位取代的5-(3,4,5-三甲氧基苯基)噻唑衍生物及其制备方法和用途 |
| BR112016016098A2 (pt) * | 2014-01-09 | 2017-08-08 | Intracellular Therapies Inc | Compostos orgânicos |
| CN107257796A (zh) * | 2014-12-02 | 2017-10-17 | 拜耳医药股份有限公司 | 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途 |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| KR20250099459A (ko) | 2015-11-03 | 2025-07-01 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 그의 용도 |
| EP3442980B1 (en) * | 2016-04-15 | 2021-06-09 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| CN110072865B (zh) * | 2017-02-08 | 2022-02-11 | 中国医药研究开发中心有限公司 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| US20240226098A1 (en) | 2020-02-28 | 2024-07-11 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20230167093A1 (en) | 2020-04-08 | 2023-06-01 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| KR20230004575A (ko) | 2020-04-08 | 2023-01-06 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| TWI782504B (zh) | 2020-05-08 | 2022-11-01 | 美商美國禮來大藥廠 | (三氟甲基)嘧啶-2-胺化合物 |
| GB202011996D0 (en) | 2020-07-31 | 2020-09-16 | Adorx Therapeutics Ltd | Antagonist compounds |
| GB202019622D0 (en) | 2020-12-11 | 2021-01-27 | Adorx Therapeutics Ltd | Antagonist compounds |
| WO2022130290A1 (en) | 2020-12-16 | 2022-06-23 | New Frontier Labs, Llc | Dicarboxylic acid esters for the treatment of diseases and conditions associated with phospholipase d toxin |
| US11845760B2 (en) | 2020-12-16 | 2023-12-19 | Amgen Inc. | PRMT5 inhibitors |
| MX2023006728A (es) | 2020-12-16 | 2023-06-19 | New Frontier Labs Llc | Esteres de acido dicarboxilico para inducir un efecto analgesico. |
-
2021
- 2021-05-06 BR BR112022022437A patent/BR112022022437A2/pt unknown
- 2021-05-06 AU AU2021266433A patent/AU2021266433A1/en active Pending
- 2021-05-06 EP EP21726445.6A patent/EP4146654A1/en active Pending
- 2021-05-06 US US17/923,374 patent/US12617796B2/en active Active
- 2021-05-06 KR KR1020227042714A patent/KR20230035236A/ko active Pending
- 2021-05-06 IL IL297963A patent/IL297963A/en unknown
- 2021-05-06 MX MX2022013946A patent/MX2022013946A/es unknown
- 2021-05-06 GB GB2217519.4A patent/GB2609879B/en active Active
- 2021-05-06 CA CA3181354A patent/CA3181354A1/en active Pending
- 2021-05-06 PE PE2022002570A patent/PE20230769A1/es unknown
- 2021-05-06 CN CN202180047824.2A patent/CN115996929B/zh active Active
- 2021-05-06 CN CN202511968176.0A patent/CN122010947A/zh active Pending
- 2021-05-06 JP JP2022567895A patent/JP7724239B2/ja active Active
- 2021-05-06 WO PCT/GB2021/051106 patent/WO2021224636A1/en not_active Ceased
- 2021-05-06 PH PH1/2022/552987A patent/PH12022552987A1/en unknown
-
2022
- 2022-11-04 CL CL2022003055A patent/CL2022003055A1/es unknown
- 2022-12-01 EC ECSENADI202291613A patent/ECSP22091613A/es unknown
- 2022-12-06 CO CONC2022/0017618A patent/CO2022017618A2/es unknown
-
2025
- 2025-08-04 JP JP2025130117A patent/JP2025183201A/ja active Pending
- 2025-10-19 IL IL324071A patent/IL324071A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021266433A1 (en) | 2022-12-15 |
| CN115996929A (zh) | 2023-04-21 |
| CN115996929B (zh) | 2026-01-13 |
| CL2022003055A1 (es) | 2023-07-07 |
| US12617796B2 (en) | 2026-05-05 |
| CA3181354A1 (en) | 2021-11-11 |
| US20230203041A1 (en) | 2023-06-29 |
| MX2022013946A (es) | 2023-02-01 |
| KR20230035236A (ko) | 2023-03-13 |
| IL324071A (en) | 2025-12-01 |
| WO2021224636A1 (en) | 2021-11-11 |
| BR112022022437A2 (pt) | 2023-01-03 |
| IL297963A (en) | 2023-01-01 |
| JP2023525762A (ja) | 2023-06-19 |
| JP2025183201A (ja) | 2025-12-16 |
| PE20230769A1 (es) | 2023-05-09 |
| GB202217519D0 (en) | 2023-01-04 |
| PH12022552987A1 (en) | 2024-02-26 |
| GB2609879B (en) | 2023-08-16 |
| GB2609879A (en) | 2023-02-15 |
| JP7724239B2 (ja) | 2025-08-15 |
| EP4146654A1 (en) | 2023-03-15 |
| ECSP22091613A (es) | 2023-03-31 |
| CN122010947A (zh) | 2026-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003055A1 (es) | Antagonistas del receptor de adenosina a2a | |
| MX2022006700A (es) | Compuestos poliheterociclicos como inhibidores de mettl3. | |
| MX2018012609A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| CL2022003185A1 (es) | Midazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b ((sol. div. 202002198) | |
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| ECSP24014832A (es) | Inhibidores de nlrp3 | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| CL2018001484A1 (es) | Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting). | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| ECSP21036982A (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso | |
| CU20110212A7 (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
| MX2023001324A (es) | Compuestos antagonistas. | |
| CO2022003457A2 (es) | Triazolopirimidinas como inhibidores de a2a/a2b | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| CU20150056A7 (es) | Derivados e 1h- bencimidazol como antagonistas de ep4 y medicamentos que los contienen | |
| CU24519B1 (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| MX2023006881A (es) | Antagonistas del receptor de adenosina a2a. | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| DOP2022000203A (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52 | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| CL2023002632A1 (es) | Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1 | |
| CO2018003756A2 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida | |
| MX2025009815A (es) | Inhibidores de la integrina alfa4beta7 macrociclica | |
| CO2024011399A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |